Kevin Peacock currently serves as AVEO’s Senior Vice President of Marketing. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.
Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations. He has over 20 years of commercial pharmaceutical and biotechnology experience, including 15 years developing and commercializing oncology products. At AVEO, in addition to developing the Company’s commercial strategy and infrastructure, Mr. Ferraresso has played a key role in business development activities, including the Company’s immuno-oncology clinical collaborations and the over $400 million agreement amendment with Kyowa Kirin for non-oncology rights to tivozanib in AVEO’s territories. Prior to joining AVEO, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics, and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing, and field deployment models and has launched Oprapred™, Plenaxis™, Zyflo™ and Feraheme™. Mr. Ferraresso holds a BA degree in Economics from Assumption College.
Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.
Lisa Bruneau brings to AVEO more than 20 years of financial and public company experience in the life sciences industry. She joined AVEO in 2016 as the Vice President of Financial Accounting and Reporting and Treasurer. Ms. Bruneau joined AVEO from Synta Pharmaceuticals, where she served as Senior Director of Finance and Director of Finance since 2004, including the company’s initial public offering. Prior to Synta, Ms. Bruneau worked at Diomed and Acambis (formerly OraVax) where she held various positions of increasing responsibility in finance and accounting, including OraVax’s initial public offering. Ms. Bruneau holds a B.S. in Business, Accounting and Finance from Bridgewater State College and an M.B.A. in International Business from Suffolk University in Boston.